The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
We herein present an overview of the upcoming 5th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …
Diffuse large B-cell lymphoma
S Li, KH Young, LJ Medeiros - Pathology, 2018 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …
worldwide, representing approximately 30–40% of all cases in different geographic regions …
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
WH Wilson, GW Wright, B Hodkinson… - Cancer cell, 2021 - cell.com
In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium
LJ Nastoupil, MD Jain, L Feng, JY Spiegel… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell …
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell …
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood …, 2020 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
Inferring gene expression from cell-free DNA fragmentation profiles
Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …
noninvasive cancer detection. Chromatin fragmentation features have previously been …
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Biological heterogeneity in diffuse large B cell lymphoma (DLBCL) is partly driven by cell-of-
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma
GS Nowakowski, A Chiappella… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …
Chimeric antigen receptor T cells in refractory B-cell lymphomas
SJ Schuster, J Svoboda, EA Chong… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with diffuse large B-cell lymphoma or follicular lymphoma that is
refractory to or that relapses after immunochemotherapy and transplantation have a poor …
refractory to or that relapses after immunochemotherapy and transplantation have a poor …